MedLab Clinical (ASX:MDC)

  • Symbol:ASX:MDC
  • Sector:Healthcare
  • Industry:Biotechnology
  • CEO:Dr. Sean Hall
  • Founded:2012
Categories:

MedLab Clinical (ASX:MDC) Stock Price

Disclaimer: Past performance is not an indicator of future performance.

MedLab Clinical (ASX:MDC) Company Overview

MedLab Clinical Limited (ASX:MDC) is a healthcare company with a focus on providing therapeutic pathways for chronic diseases. The company operates primarily out of Australia—with an organic chemistry set up in Southern California and additional offices in Malta and London—and has a market capitalisation of approximately $80 million.

MedLab is currently involved in the development of numerous medicinal products targeting everything from antibiotics to insulin, as well as therapies aimed at treating conditions such obesity and depression. However, it has been attracting serious attention for its research into cannabis-based medicine targeted at pain management—particularly chronic oncology pain—which is an increasingly lucrative field.

The company takes a research-driven approach to the market and has a diversified product offering which already includes several cannabinoid products such as NanaBis and NanaBidial. MedLab have also developed a nano-particle medicine delivery system known as Nanocelle, which is being applied to its medicines, off-patent drugs and nutritional products.

Stay updated about
this company

Signup to get updates.